Wuhan Hvsen Biotechnology Co Ltd Asset Resilience Ratio

Latest as of June 2026: 6.29%

Wuhan Hvsen Biotechnology Co Ltd asset resilience ratio. Wuhan Hvsen Biotechnology Co Ltd (300871) has an Asset Resilience Ratio of 6.29% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Wuhan Hvsen Biotechnology Co Ltd to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥214.41 Million
≈ $31.37 Million USD Cash + Short-term Investments

Total Assets

CN¥3.41 Billion
≈ $498.82 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Wuhan Hvsen Biotechnology Co Ltd (2020–2025)

Asset resilience ratio of Wuhan Hvsen Biotechnology Co Ltd from 2020 to 2025. This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read Wuhan Hvsen Biotechnology Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Wuhan Hvsen Biotechnology Co Ltd's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥214.41 Million 6.29%
Total Liquid Assets CN¥214.41 Million 6.29%

Asset Resilience Insights

  • Limited Liquidity: Wuhan Hvsen Biotechnology Co Ltd maintains only 6.29% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Wuhan Hvsen Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Hvsen Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Wuhan Hvsen Biotechnology Co Ltd Asset Resilience Ratio by Year (2020–2025)

Wuhan Hvsen Biotechnology Co Ltd asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Wuhan Hvsen Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.33% CN¥160.33 Million
≈ $23.46 Million
CN¥3.01 Billion
≈ $440.25 Million
-1.34pp
2024-12-31 6.67% CN¥200.97 Million
≈ $29.41 Million
CN¥3.01 Billion
≈ $441.14 Million
-3.56pp
2023-12-31 10.23% CN¥304.26 Million
≈ $44.52 Million
CN¥2.98 Billion
≈ $435.40 Million
-1.87pp
2022-12-31 12.10% CN¥361.68 Million
≈ $52.92 Million
CN¥2.99 Billion
≈ $437.40 Million
+11.00pp
2021-12-31 1.10% CN¥30.22 Million
≈ $4.42 Million
CN¥2.74 Billion
≈ $401.19 Million
-12.63pp
2020-12-31 13.73% CN¥240.63 Million
≈ $35.21 Million
CN¥1.75 Billion
≈ $256.41 Million
--
pp = percentage points

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology
Market Cap
$509.35 Million
CN¥3.48 Billion CNY
Market Cap Rank
#11832 Global
#3359 in China
Share Price
CN¥17.25
Change (1 day)
+1.95%
52-Week Range
CN¥16.58 - CN¥32.62
All Time High
CN¥48.84
About

Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildi… Read more